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The goal of the present work was to identify the candidate genetic markers predictive of alloimmunization in sickle cell disease
(SCD). Red blood cell (RBC) transfusion is indicated for acute treatment, prevention, and abrogation of some complications of SCD.
Awell-known consequence ofmultiple RBC transfusions is alloimmunization. Given that a subset of SCDpatients developmultiple
RBC allo-/autoantibodies, while others do not in a similar multiple transfusional setting, we investigated a possible genetic basis for
alloimmunization. Biomarker(s) which predicts (predict) susceptibility to alloimmunization could identify patients at risk before
the onset of a transfusion program and thus may have important implications for clinical management. In addition, such markers
could shed light on the mechanism(s) underlying alloimmunization. We genotyped 27 single nucleotide polymorphisms (SNPs)
in the CD81, CHRNA10, and ARHG genes in two groups of SCD patients. One group (35) of patients developed alloantibodies,
and another (40) had no alloantibodies despite having received multiple transfusions. Two SNPs in the CD81 gene, that encodes
molecule involved in the signal modulation of B lymphocytes, show a strong association with alloimmunization. If confirmed in
prospective studies with larger cohorts, the two SNPs identified in this retrospective study could serve as predictive biomarkers for
alloimmunization.
1. Introduction
Transfusion of red blood cells (RBCs) is a key component
of the comprehensive management of patients with SCD
[1]. Transfusion increases the oxygen carrying capacity of
blood by increasing hemoglobin A [2, 3] and decreasing
hemoglobin S [4–7]. Further, transfusion decreases blood
viscosity, improves blood flow, and suppresses endogenous
erythropoiesis. Due to these benefits, most SCD patients
receive multiple RBC transfusions in their lifetime. RBC
transfusion therapy is complicated by development of anti-
bodies specific for allelic (alloantibodies) or self (autoanti-
bodies) RBC determinants. Alloantibodies are more frequent
than autoantibodies, whose clinical significance remains
questionable. The presence of anti-RBC antibodies in SCD
patients may cause delay in finding suitable blood donors,
which can result in life threatening anemia. In addition, anti-
RBC antibodies may cause delayed hemolytic transfusion
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reactions, which resemble sickle cell crises and can be lethal
[8–10]. Finally, anti-HLA antibodies promoting rejection of
hematopoietic cell grafts are more frequent in patients with
anti-RBC antibodies [11]. Identification of biomarker(s) pre-
dictive of susceptibility to alloimmunization could identify
a subpopulation of SCD patients at risk before the onset of
a transfusion program and thus has important implications
for their clinical management. In addition, such markers
could assist in enhancing our insight into the mechanism(s)
underlying alloimmunization.
RBC alloantibodies develop in 18–47% of patients with
SCD [3, 12–15]. These rates are higher than 0.2–2.8% found
in transfused patients without SCD [16–19]. One possi-
ble explanation for these high rates is antigenic disparity-
different blood group distribution between predominantly
Caucasians blood donors and SCD patients who are of
African or African-Caribbean descent [20]. This concept is
supported by alloimmunization frequencies in SCD patients
in Saudi Arabia (13.7%), Uganda (6.1%), Egypt (21.4%),
and Tunisia (16.6%) where blood donors and SCD patients
are from similar ethnic background [21–24]. Even lower
alloimmunization rates (2.6%) were noted in a Jamaican
patient cohort [25], but they might have been second to very
low number of units received (1-2 per patient). However, even
these reduced rates are higher than the above mentioned
“background” rate of 0.2–2.8%, suggesting a multifaceted
etiology of alloimmunization.
The human population in Africa has been subject to
selection pressures imposed by infectious agents. One of
the best-documented examples is malaria which significantly
shaped the genetic make-up in several regions of Africa
[26]. The most prominent genetic trait is 𝐻𝑏𝛽𝑆 heterozy-
gosity that confers about 10-fold increase in protection
against life-threatening forms of plasmodium falciparum
malaria [27]. Malaria infection has also exerted pressure for
stronger immune responsiveness as evidenced by association
of polymorphic variants in HLA-B, HLA-DR, IL-4, CD40L,
FcGR2A, and TNF𝛼 which result in increased resistance to
malaria [26]. We reasoned that there may be other as yet
undiscovered malaria-selected polymorphisms that promote
stronger immune responsiveness and that some of them
may lie close to Hb𝛽. Such neighboring immune response-
modifying genetic markers are more likely to segregate with
𝐻𝑏𝛽
𝑆 than those located farther away on the same chromo-
some, or those located on other chromosomes. We therefore
hypothesized that two malaria-protective polymorphisms
were coselected: the 𝐻𝑏𝛽𝑆 and an allele of a near-by gene,
encoding a molecule with immunomodulatory function.The
consequence of such coselection by heterozygosity would
result in an undesired, exacerbated immune response in
homozygous 𝐻𝑏𝛽𝑆 individuals, with an eventual increase in
the incidence of alloantibody response following transfusion.
The closest gene of immune interest to the HBB locus is
the gene encoding Sjogren Syndrome Antigen 1. Although
we have recently demonstrated an association of a SNP in
this gene with tolerance induction in early childhood [28],
we found no evidence of association with alloimmunization
per se, which prompted us to continue our search for
other genes in the neighborhood of Hb𝛽 gene. We herein
identified a strong association of alloimmunization with two
single nucleotide polymorphisms (SNPs) in the CD81 gene
encoding for a molecule involved in the signal modulation of
B lymphocytes which qualify them as predictive markers of
alloimmunization.
2. Materials and Methods
2.1. Subjects. Seventy-five adult SCD patients (44 Females,
median age 32 years, range 21–73; 31 males, median age 30
years, range 20–58) regularly followed at Tenon Hospital in
Paris, France were recruited for the study. All specimens were
belonging to the larger French repository of blood samples
from recipients of chronic RBC transfusion, financially sup-
ported and initiated in 1987 by the Institut National de la
Transfusion Sanguine. Patients are first or second generation
immigrants from Sub-Saharan Africa, that is, Atlantic West
Africa, Central West Africa, and Bantu-speaking Africa (62
patients), and 13 patients were from the French West Indies.
Patients were unrelated to each other and were not part of the
same family. Samples were obtained during a routine clinical
consultation at the steady state; a clinical status characterized
by the absence of any infectious process or acute complication
(such as vasoocclusive crisis) in the 3 months preceding
the consultation. Patients were enrolled in this observational
cross-sectional study after obtaining their informed consent
according to the ethical research committee of “Assitance
Publique-Hopitaux de Paris (AP-HP)” at Tenon Hospital.
The criteria for inclusion were: (1) the diagnosis of sickle
cell anemia (made using standard laboratory procedures
including complete blood count, hemoglobin electrophoresis
and family studies, and by direct molecular identification
of the Hb𝛽 mutation) and (2) having received at least five
RBC transfusions matched for AB0 and RhD blood anti-
gens. Alloimmunized patients were received antigen negative
blood for identified alloantibodies [40]. All patients received
RBC transfusions during their in- or outpatient treatment
at Tenon Hospital. Leukoreduced RBC units were collected
and distributed by “Etablissement Francais du Sang (EFS).”
Patients receiving hydroxyurea therapy (HU) were identified
in each group to evaluate the influence of this therapy on the
incidence of alloimmunization (Table 1). The mean ages of
the patients at the time of the study were 35.1 ± 8.4 years
(mean ± SD) and 30.9 ± 8.7 years (mean ± SD) for patients
with and without alloimmunization, respectively (Table 1).
The mean of age, gender, number of RBC transfusions and
exposure to hydroxyurea did not vary significantly between
alloimmunized and nonalloimmunized patients.
2.2. SNP Detection. Genotyping was performed using a
TaqMan allelic discrimination assay that employs the 5󸀠
nuclease activity of Taq polymerase to detect a fluorescent
reporter signal. Allele-specific oligonucleotides designed by
Applied Biosystems, (Foster City, CA, USA) were labeled
with different fluorophores in order to detect both alleles
simultaneously. Genotypes were determined by the ratio of
the two fluorophores used. The PCR for each SNP contained
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Table 1: Clinical and demographic characteristics of SCD patients.
Alloimmunized Non-alloimmunized P value
(𝑁 = 35) (𝑁 = 40)
Age
Mean age ± SD 35.1 ± 14 30.9 ± 8.7 NS
Range (21 y–73 y) (20 y–58 y)
Gender
Male 14 17 NS
Female 21 23
RBC transfusion
<30 unit 25 25 NS
>30 unit 10 15
Hydroxyurea
Yes 11 17 NS
No 24 23
Table 2: Distribution and specificities of alloantibodies.
Blood group
system Alloantibody specificity
Number of
alloantibodies
Rh D, D partial, C, C partial, c, C
w,
E, rhi, and V
24
Kell K and Kpa 4
Duffy Fya, Fya,b, and Fy5 9
Lewis Lea and Leb 1
Kidd Jka and Jkb 7
MNS M and S 4
Dombrock Hy 1
Colton Cob 1
Cartwright Ytb 1
Other blood
group systems Kn
a, Knb, and Bga 3
20 ng of DNA, 900 nM primers, 200 nM probes, and TaqMan
Universal PCR Master Mix, in a final volume of 15𝜇L. PCR
was performed on an MJ Research Tetrad thermal cycler
(Waltham, MA, USA). The PCR profile was 10 minutes at
95∘C (denaturation), 44 cycles of 15 seconds at 92∘C, and
1 minute at an annealing temperature of 60∘C. Reactions
were set up using a MWG robot, and fluorescence ratios
and allele calling were done using an ABI 7900. For the
quality control of our genotyping, 10% of samples were
randomly tested in three independent setup, and genotypes
were compared. There was 100% concordance of genotypes
in all three replicates.
2.3. 𝛽-Globin Gene Locus Genotype. Beta-globin gene haplo-
types were determined by PCR-RFLP as previously described
[43].
2.4. Statistical Analysis. The association of SNPs with alloim-
munization was performed using the Chi-square testing with
Yate’s correction or Fisher’s exact test when appropriate. After
Bonferroni adjustment for multiple testing, the findings were
considered statistically significant if 𝑃 value was equal or less
than 0.00185.
3. Results
3.1. Alloantibodies. Thirty-five of 75 adult patients (47%) had
clinically significant RBC alloantibodies, listed in Table 2
(except for the Lea and Leb-specific antibodies that were con-
sidered clinically not significant).The incidence of alloimmu-
nization in males (14 of 31 males who received transfusion
were 45%) and females (21 of 44 females who received
transfusion were 48%) was not significantly different. The
number of alloantibodies per patient ranged from 1 to 9.
Twenty patients had one alloantibody, eight patients had two,
and nine patients had three or more antibodies. In twenty-
eight patients (80%) who developed significant alloantibod-
ies, the specificity was directed against antigens in the Rh or
Kell systems. Five patients developed antibodies in the Rh
system with uncommon specificity (Cw, partial D, partial C,
V, and rhi). However, twenty one patients (60%) developed
additional alloantibodies to antigens in the Duffy, Kidd,
Lewis, and MNS systems, and six patients (17%) developed
additional antibodies to antigens in uncommon blood group
systems.
3.2. Selection of SNPs for Analysis. There are several genes
located in the vicinity of the HBB locus that can potentially
impact the immune system (Table 3), with literally hundreds
of SNPs identified in each. Given the plethora of candidate
SNPs, we identified two sets of criteria to establish the priority
for SNP analysis as following.
(1) Criteria related to the selection of genes:
(a) closeness of the gene to the 𝐻𝑏𝛽 globin gene
(the closer the genes are, the more likely the
alleles are in linkage disequilibrium (LD));
(b) involvement of the gene product in immune
response;
(c) preserved homology of the genes between spec-
ies (the less homologous genes are likely to pro-
duce a “high background” of genetic variation
against which it is more difficult to detect gene-
tic associations).
(2) Criteria related to the SNPs selection:
(a) known association of a polymorphism with an
immune phenomenon;
(b) SNP frequency difference (HapMap database)
between Yoruba (YRI) in Ibadan, Nigeria, and
CEPH (Utah residents with ancestry from nor-
thern and western Europe: CEU) [44];
(c) characterization of SNPs by the HapMap data-
base as informative for the linkage disequilib-
rium in haplotype analysis using the software
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Table 3: List of genes in the proximity of HBB locus encoding molecules affecting the function of the immune system.
Gene symbol Distance from
HBB locus (MB) Molecule Effects on the immune system
Sequence homology
P.
troglodytes
M.
musculus
Rattus
norvegicus
Canis
familiaris
SSA1 0.83 SSA1, Ro52,and TRIM21
Encodes Ro52 antigen in Sjogren
Syndrome and lupus [29] 99 69 68 67
ARHG 1.38 RhoG Stronger immune function inknock-out mice [30] 100 100 100 99
CHRNA10 1.55 𝛼10 subunitof AchR
Modulates T-cell Ca2+ mobilization
[31] 100 91 90 88, 92
∗
CD81 2.85 CD81 Modulates BCR signaling [32, 33] 99 91 93 83
PHEMX/TSSC6 2.92 TSSC6 Higher T-cell responses inknock-out mice [34] NA 63 57 NA
LSP1 3.41 LSP1 Regulation of B cell apoptosis [35] 100 67 64 82, 88∗
TOLLIP 3.95 Toll inh. prot. Downmodulates IL-1 and TNF𝛼signalings [36] 72 93 93 67
CD151 4.39 CD151 Represents blood group antigenMER-2 [37] 98 93 92 94
IRF7 4.60 IRF7 Interferon production [38] 96 62 63 NA
SIGIRR 4.80 SIGIRR Negative regulator of IL-1 signaling[39] 98 73 82 NA
∗Only partial sequence of canine CHRNA10 and LSP1 genes is available. Distinct numbers represent homology of different available gene segments.
Haploview version 3.2 ( http://www.broadinstit-
ute.org/). The HapMap database provides infor-
mation on millions of SNPs that determine the
variation among human beings. This database
provides the frequency for each SNP located in
the noncoding region of the genome.
Based on the above criteria, we examined HapMap-
designated-informative SNPs inARHG,CHRNA10, andCD81
genes.
3.3. Association of CD81 SNPs and Alloimmunization. Table 4
summarizes the results of association analysis of alloimmu-
nization with 27 SNPs, all located in the noncoding regions of
appropriate genes. Overall, allelic distribution was similar to
that reported in the general population in Sub-Saharan region
(HapMap; NCBI). For some patients, we were unable to
establish a genotype despite repeated attempts.These patients
may have previously undescribed/novel alleles or additional
polymorphisms in the primer-binding regions.Therefore, the
total number of patients for some SNPs do not equal the 35
(alloimmunized) or 40 (nonalloimmunized). Of the 27 SNPs
studied, two had a statistically significant association with
alloimmunization. Both SNPs are located in the CD81 gene
and, based on the haploview analysis of disequilibrium link-
age data, are in general not coinherited. Consistent with this,
the “informative” genotypes (defined as those that differmost
between the alloimmunized and nonimmunized patients-
CC in rs708564 andCC in rs2237863) were not coinherited in
most patients.Of the 28 patientswith rs708564C/Cgenotype,
9 also had the rs2237863 C/C genotype. The presence of at
least one of the “informative” genotypes was present in 37 out
of 75 patients (49%).The presence of “informative” genotypes
correctly “predicted” alloimmunization status in 30 out of 40
SCD patients (75%) with no antibodies detected, and only in
6 of 35 patients (17%) with antibodies (Table 5). The absence
of both two “informative” genotypes occurred in 29 out of 35
patients with antibodies (83%) and in 10 out of 40 patients
without antibodies (25%). Thus, these SNPs may serve as a
powerful predictor of alloimmunization.
3.4. Hemoglobin 𝛽 Haplotypes. The existence of five 𝐻𝑏𝛽𝑆
haplotypes suggested that the𝐻𝑏𝛽𝑆 mutation arose indepen-
dently in different geographical regions [45, 46]. The coin-
heritance of𝐻𝑏𝛽𝑆 neighboring DNA markers, including the
ones affecting alloimmunization, could also have selectively
occurred in one or several independently derived haplotypes.
Therefore, we studied the 𝐻𝑏𝛽𝑆 haplotypes in this patient
cohort. Only patients homozygous for Bantu and Benin hap-
lotypes were present in numbers sufficient to allow statistical
analysis (Table 5). The predictive power of rs708564C/C
and/or rs2237863C/C CD81 SNP genotypes was preserved in
subgroups of patients with Bantu/Bantu, Benin/Benin, or all
other𝐻𝑏𝛽𝑆 haplotypes grouped together. These data suggest
that CD81 SNPs in our subject population were inherited
independently of any particular𝐻𝑏𝛽𝑆 haplotype.
4. Discussion
Blood and blood product transfusion most frequently either
provoke no obvious immune reaction or induce immune sup-
pression. The latter, known as transfusion-related immuno-
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Table 4: SNP genotype association with alloimmunization in SCD.
SNP Gene Genotypes Number of patients
∗
𝑃 value HapMap#
Antibody positive Antibody negative
(1) rs1049388 ARHG CC/CG/GG 21/8/0 21/11/0 0.593273 62/30/8
(2) rs1451724 ARHG AA/AG/GG 1/3/27 0/3/29 0.833054 0/23/77
(3) rs4910852 ARHG AA/AG/GG 25/7/0 18/10/0 0.264449 61/30/9
(4) rs7128013 ARHG AA/AC/CC 13/12/5 11/18/4 0.543399 25/49/26
(5) rs7929197 ARHG CC/CT/TT 7/13/12 8/12/5 0.429608 30/45/25
(6) rs10742177 ARHG CC/CG/GG 10/14/7 18/3/5 0.008979 41/45/14
(7) rs10835182 ARHG AA/AT/TT 0/14/15 0/12/20 0.444898 2/23/75
(8) rs10835184 ARHG AA/AT/TT 25/2/0 26/2/2 0.550071 95/5/0
(9) rs12272393 ARHG AA/AC/CC 7/13/14 8/12/11 0.817062 30/45/25
(10) rs17173879 ARHG AA/AG/GG 30/2/0 25/1/0 0.999999 93/7/0
(11) rs2231529 CHRNA CC/CT 27/3/1 35/2/0 0.493847 93/7/0
(12) rs2231532 CHRNA AA/AG/GG 19/13/3 14/12/5 0.609984 63/35/2
(13) rs2271583 CHRNA AA/AG/GG 4/14/15 2/9/18 0.422893 10/33/57
(14) rs2672213 CHRNA CC/CT/TT 30/2/0 23/4/0 0.397881 97/3/0
(15) rs2672216 CHRNA CC/CT/TT 32/2/0 25/8/1 0.062890 85/13/2
(16) rs2741862 CHRNA CC/CT/TT 5/25/4 14/14/5 0.022396 23/35/42
(17) rs12221525 CHRNA CC/CG/GG 20/8/4 20/11/2 0.562563 50/37/13
(18) rs708564∗∗ CD81 CC/CT/TT 5/15/11 23/8/3 0.000086## 82/17/2
(19) rs731909 CD81 CC/CG/GG 27/6/3 33/2/0 0.064002 90/8/2
(20) rs756915 CD81 CC/CT/TT 9/19/8 12/14/10 0.495260 21/50/29
(21) rs800137 CD81 CC/CT/TT 6/16/13 14/14/7 0.086688 46/31/24
(22) rs800335 CD81 CC/CT/TT 7/10/18 4/8/24 0.374866 82/17/2
(23) rs874330 CD81 CC/CT/TT 13/15/7 19/9/7 0.284287 52/40/8
(24) rs2019938 CD81 AA/AG/GG 11/13/5 15/14/8 0.851861 43/33/23
(25) rs2237863 CD81 CC/CT/TT 3/22/5 15/10/6 0.001518## 15/47/38
(26) rs11022565 CD81 GG/GT/TT 17/14/4 21/7/5 0.280369 61/32/7
(27) rs11022567 CD81 AA/AG/GG 5/14/16 5/7/25 0.120284 7/33/60
∗Patient numbers are displayed in the order shown in the column labeled genotypes. #Relative distribution of genotypes in Sub-Saharan population, as reported
by the HapMap.This research utilizes the NCBI SNP database [41], (http://www.ncbi.nih.gov/snp/).The Single Nucleotide Polymorphism database (dbSNP) is
a public domain archive for a broad collection of simple genetic polymorphisms. dbSNP reports many cases of SNPs genotyped by HapMap and other projects
which provide additional genotype and allele frequency information. ∗∗NCBI database describes two additional alleles, A/Gwith very low frequencies (<0.5%)
for rs708564. This might be due to a mutational mechanism that leads to the simultaneous creation of two new base pairs at the same site which is beyond the
scope of this study [42]. Our results, however, are based on the two reference SNPs alleles (C/T) of rs708564. ##𝑃 values significant comparing SCD patients
with and without alloimmunization.
Table 5: Hb𝛽S genotypes in SCD patients with or without antibodies or with “informative” SNP genotypes.
Hb𝛽S haplotype Total patients
Antibody positive Antibody negative
𝑃 valueAt least one C/C
genotype∗
No C/C
genotypes∗
At least one C/C
genotype∗
No C/C
genotypes∗
Bantu/Bantu 15 2 6 7 0 0.0069
Benin/Benin 28 1 10 12 5 0.0021
Other∗∗ 33 3 13 11 5 0.0113
Total 75 6 29 30 10 6.17 × 10−7
∗Patients were divided into groups that had rs708564C/C and/or rs22378563C/C genotypes (group one) or were double negative for these genotypes (group
two).
∗∗Includes any haplotypes found in 10 or less subjects (Senegal/Senegal; Benin/Cameroon; Senegal/Benin; Cameroon/Cameroon; Benin/Bantu; Bantu/
Cameroon; Senegal/Cameroon; Benin/𝛽thal; and Senegal/𝛽thal).
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modulation, may reduce transplant rejection rate and pro-
mote cancer recurrence, postoperative infections, and virus
activation [47, 48]. So, what is (are) the factor(s) in some
transfusion settings that converts an inert or tolerogenic
event into an immunogenic one, leading to alloimmuniza-
tion? And why the alloimmunization rates are higher in
subjects with SCD? One theory is that discrepancies in
RBC antigen protein structures between blood donors and
recipients enhance the stimulation of B-cell clones to produce
glycoprotein-specific alloantibodies. Blood group distribu-
tion is different between predominantly Caucasians blood
donors and SCD patients who are of African or African-
Caribbean descent. The SCD patients in the present study
are mostly first/second generation Africans or West Indies
whereas blood donors are mostly Caucasians. Hence, the
antigen disparity between donor and recipients can explain
at least in part the relatively high rate of alloimmunization
(44%) in our patient population.
Transfusion-nonrelated preexisting recipient conditions
that may lead to increased inflammation and activation of
innate immunity are thought to contribute to alloantibody
development [49, 50]. This has certainly been shown in a
mouse model of alloimmunization [51]. SCD patients display
increased inflammation and activation of innate immunity
[52, 53] and increased levels of serum cytokines [54–57].
While antigenic disparity and proinflammatory milieu are
important factors for higher rates of alloimmunization in
SCD, it still remains unclear why the majority of RBC
recipients never develop allo-/autoantibodies despite mul-
tiple transfusions. We therefore hypothesized that immune
response to RBC alloantigens is additionally influenced by
inheritable variations of immune function. We searched
for genetic variations in the vicinity of Hb𝛽 locus because
one of the several susceptibility loci for development of
autoimmune/inflammatory diseases is located on chromo-
some 11p15, in proximity of Hb𝛽 [58]. Although the present
work does not constitute a proof for the above hypothesis,
it provides the first of several steps towards that goal. If
confirmed in larger patient cohorts, the work may lead to
the discovery of markers of alloimmunization-genetic traits
that associate with alloimmunization, but do not necessarily
cause or prevent alloimmunization. Although CD81 is in the
relative vicinity of the Hb𝛽 locus, the distance is large enough
to suggest that the linkage disequilibrium is not a likely
mechanism of association.
CD81 is a molecule which participates in the formation
of so-called tetraspanin web that promotes cisassociations
with different cell surface receptors including CD19/CD21 in
B cells CD4 and CD8 in T cells [59, 60]. This association has
functional consequences in B-cell-related pathways. Indeed,
enhanced activation is observed in CD81 deficient B cells
[32] and the use of antibodies to CD81 alter CD19/CD21-
mediated signaling [33]. In addition, CD81 is a part of a
complex involved in the uptake of exosomes by dendritic
cells [61] and canmodulate chemokine-induced dendritic cell
migration [62].Thus, CD81 can influence the immune system
at multiple levels,b c and the identified SNPs may affect the
function of CD81 protein at any of these steps. An alternative
explanation is that markers may have an indirect effect on
CD81, or may be associated with alloimmunization through
linkage disequilibrium to a yet to be identified functional
variant within CD81 gene or another gene.
SCD is caused by homozygous mutation in a single gene
(Hb𝛽, glu6val), but it has exceptional phenotypic variability.
This is explained by the interaction of environmental factors
with a select group of polymorphic genes. Understanding
whether there are genetic modifiers responsible for the
phenotypic variability in clinical disease manifestations may
provide novel approaches to treatment. The most studied
genetic modifiers affecting the severity of SCD are the level
ofHbF expression, BCL11A, HBS1L-MYB, and coinheritance
of 𝛼-thalassemia [63–65]. Other modifier genes include IL-
4R, TGF𝛽R3, adenylate cyclase, and HLA-DPB1∗0401 where
certain allelic variants predispose SCD patients to large
vessel stroke [26, 66, 67]. SNPs in bone morphogenetic
protein receptor 2 (BMPR2) is associated with familial and
sporadic pulmonary hypertension [68–70], and acute chest
syndrome inwomenwith SCD is associated with a SNP in the
endothelial nitric oxide synthase gene (NOS3) [71]. Sickle cell
adhesion to laminin may be partially dependent on SNPs in
the 𝛽-adrenergic receptor gene (ADRB2) and adenylate cyclase
(ADCY6) gene [72]. Susceptibility to infection in SCD has
been associatedwith polymorphism inHLA class II gene.The
data shows a protective role of HLA-DRB1∗15 against infec-
tion, in contrast to HLA-DQB1∗03 which predisposes the
SCD patients to a higher risk of infection such as meningitis,
septicemia and osteomyelitis [73]. In contrast, somepolymor-
phisms in TNF𝛼, 𝛽-adrenergic receptor 2 (ADRB2) andHLA-
DPB1∗1701 were protective against stroke [74]. Given the
plethora of studies addressing genetic influences on different
aspects of SCD, it is surprising that genetic modulation of
alloimmunization has been virtually unexplored. One study
has reported the possible association between HLA-B35 and
RBC alloantibodies [75]. However, the study was performed
on a very small number of subjects, and the finding has not
been replicated.
5. Conclusions
Our data suggest that SNPs in CD81 gene could potentially
serve as predictors of RBC alloimmunization. The present
study will have to be expanded in independent cohort
of patients such as African-American patients with SCD.
Furthermore, the impact of the SNPs on CD81 expression,
and the role of CD81 in alloimmunization will need further
investigation to gain full understanding of the mechanism
underlying the cis-association of rs708564 and rs2237863
with alloimmunization.
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